COMP <GO>
IRWD vs ACRS // EV/EBITDA & P/E VALUATION
Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Aclaris Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IRWD 7
— ACRS 1
■ METRIC PARITY
LAST: $3.62 (+0.28%) • MKT CAP: $598.2M
valuation
3.9x
LAST: $3.99 (+0.76%) • MKT CAP: $587.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRWD VS. ACRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRWD | ACRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 73.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 21.23% | -8.04% | +29.27 | IRWD | /fcf-yield <GO> |
| Operating Margin | 33.30% | -60.00% | +93.30 | IRWD | /operating-margins <GO> |
| Net Profit Margin | 8.10% | -60.00% | +68.10 | IRWD | /net-margins <GO> |
| Revenue Growth (YoY) | -15.70% | -58.20% | +42.50 | IRWD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | IRWD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 45.5 | -5.00 | ACRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $598.2M | $587.3M | $10.8M | IRWD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRWD REV | ACRS REV | IRWD GROSS % | ACRS GROSS % | IRWD FCF | ACRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $296.2M | $7.8M | — | 73.3% | $127.0M | -$47.2M |
| FY 2024 | $351.4M | $18.7M | — | 85.1% | $103.4M | -$20.2M |
| FY 2023 | $442.7M | $31.2M | — | — | $183.4M | -$78.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRWD // BETA —
ACRS // BETA —